Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novo Nordisk L | London | Healthcare | Pharmaceuticals | £245.38B | 20.5x | 1.14 | GBX 5,490.48 | -2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AbbVie Inc | London | Healthcare | Pharmaceuticals | £244.69B | 79.1x | -3.03 | GBX 15,822.28 | -1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche Holding Participation | London | Healthcare | Pharmaceuticals | £189.12B | 26.6x | -0.89 | GBX 23,737.83 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche Holding | London | Healthcare | Pharmaceuticals | £189.12B | 26.6x | -0.9 | GBX 25,067.37 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Abbott Laboratories L | London | Healthcare | Healthcare Equipment & Supplies | £171.79B | 17.1x | 0.12 | GBX 9,896.31 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novartis | London | Healthcare | Pharmaceuticals | £169.36B | 18x | -1.33 | GBX 8,652.88 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca | London | Healthcare | Pharmaceuticals | £163.56B | 28.3x | 1.24 | GBX 10,548 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 29% Upside | Upgrade to Pro+ | |
Merck & Co Inc | London | Healthcare | Pharmaceuticals | £148.47B | 11.5x | 0.02 | GBX 5,892.67 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Gilead Sciences | London | Healthcare | Pharmaceuticals | £100.18B | 22.5x | 0.02 | GBX 8,049.43 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Essilor International | London | Healthcare | Healthcare Equipment & Supplies | £95.25B | 46.4x | 47.85 | GBX 20,623.19 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sanofi L | London | Healthcare | Pharmaceuticals | £86.28B | 16.7x | 0.41 | GBX 7,094.75 | -2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
GSK plc | London | Healthcare | Pharmaceuticals | £58.70B | 18.8x | -0.62 | GBX 1,449.50 | -2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 7.1% Upside | Upgrade to Pro+ | |
Siemens Healthineers | London | Healthcare | Healthcare Equipment & Supplies | £43.44B | 26.4x | 1.69 | GBX 3,890.53 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck KGaA | London | Healthcare | Pharmaceuticals | £40.80B | 17x | 4.9 | GBX 9,411.50 | -2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Lonza Group | London | Healthcare | Biotechnology & Medical Research | £35.99B | 58x | GBX 51,022.08 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
HALEON | London | Healthcare | Pharmaceuticals | £34.55B | 25x | 0.62 | GBX 384.30 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10.6% Upside | Upgrade to Pro+ | |
IDEXX Laboratories | London | Healthcare | Healthcare Equipment & Supplies | £31.18B | 47.7x | 9.85 | GBX 38,707.33 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
UCB L | London | Healthcare | Pharmaceuticals | £25.22B | 27.8x | 0.13 | GBX 13,346.29 | -1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
arGEN X BV | London | Healthcare | Biotechnology & Medical Research | £24.69B | 30.9x | 0.08 | GBX 40,327.04 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bayer L | London | Healthcare | Pharmaceuticals | £22.86B | -8.2x | 1.81 | GBX 2,327 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Humana | London | Healthcare | Healthcare Providers & Services | £21.91B | 17.3x | -1.4 | GBX 18,147.22 | 2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Fresenius SE Co KGaA | London | Healthcare | Healthcare Providers & Services | £20.25B | 19.9x | 0.12 | GBX 3,597.83 | -2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sandoz | London | Healthcare | Pharmaceuticals | £17.01B | GBX 3,959.01 | 3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||||
Koninklijke Philips | London | Healthcare | Healthcare Equipment & Supplies | £15.88B | 74.2x | 0.53 | GBX 1,641.99 | -1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Coloplast AS | London | Healthcare | Healthcare Equipment & Supplies | £15.57B | 29.9x | -2.96 | GBX 6,875.29 | -2.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biogen | London | Healthcare | Pharmaceuticals | £13.76B | 12.5x | 0.47 | GBX 9,451.88 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sonova Holding | London | Healthcare | Healthcare Equipment & Supplies | £13.40B | 27.2x | -2.67 | GBX 22,335.59 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Fresenius Medical Care | London | Healthcare | Healthcare Providers & Services | £11.70B | 21.9x | 0.77 | GBX 3,959.58 | -2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Cooper Companies | London | Healthcare | Healthcare Equipment & Supplies | £10.39B | 33.4x | 1.51 | GBX 5,202.95 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genmab | London | Healthcare | Biotechnology & Medical Research | £10.01B | 11.2x | 0.04 | GBX 16,253.70 | -1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Align Tech | London | Healthcare | Healthcare Equipment & Supplies | £9.73B | 32.7x | -3.43 | GBX 13,354.09 | 3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Recordati Industria | London | Healthcare | Pharmaceuticals | £9.44B | 27.1x | 3.5 | GBX 4,575.33 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Smith & Nephew | London | Healthcare | Healthcare Equipment & Supplies | £9.34B | 30.6x | 0.54 | GBX 1,067 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 16.4% Upside | Upgrade to Pro+ | |
Eurofins Scientific SE FRA | London | Healthcare | Biotechnology & Medical Research | £9.30B | 33.3x | 0.75 | GBX 5,191.07 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Orion Oyj | London | Healthcare | Pharmaceuticals | £7.59B | 25.5x | 0.42 | GBX 5,387.77 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Qiagen NV | London | Healthcare | Biotechnology & Medical Research | £7.48B | 108.3x | -1.48 | GBX 3,469.18 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Swedish Orphan Biovitrum publ | London | Healthcare | Pharmaceuticals | £7.47B | 24.6x | 0.31 | GBX 2,214.80 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ipsen L | London | Healthcare | Pharmaceuticals | £7.19B | 23.7x | -0.51 | GBX 8,711.79 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
William Demant | London | Healthcare | Healthcare Equipment & Supplies | £6.72B | 20.7x | 0.55 | GBX 3,172.77 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
ConvaTec Group | London | Healthcare | Healthcare Equipment & Supplies | £5.76B | 42.3x | 0.85 | GBX 281.80 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10.3% Upside | Upgrade to Pro+ | |
Grifols | London | Healthcare | Pharmaceuticals | £5.47B | 35.6x | GBX 890.27 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Grifols Pref | London | Healthcare | Pharmaceuticals | £5.47B | 35.6x | GBX 666.20 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Sectra AB | London | Healthcare | Healthcare Equipment & Supplies | £4.71B | 108.4x | 3.46 | GBX 2,442.46 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
ALK-ABELLO | London | Healthcare | Pharmaceuticals | £4.58B | 43.2x | 0.68 | GBX 1,713.66 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Hikma Pharma | London | Healthcare | Pharmaceuticals | £4.55B | 17.2x | 0.19 | GBX 2,066 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24.3% Upside | Upgrade to Pro+ | |
Carl Zeiss Meditec | London | Healthcare | Healthcare Equipment & Supplies | £4.43B | 33.8x | -0.82 | GBX 5,041.41 | -2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
DiaSorin | London | Healthcare | Healthcare Equipment & Supplies | £4.31B | 25.9x | GBX 7,983.31 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
H Lundbeck L | London | Healthcare | Pharmaceuticals | £4.05B | 11.6x | 0.29 | GBX 424.49 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Richter Gedeon Vegyeszeti Gyar | London | Healthcare | Pharmaceuticals | £4.03B | 7.9x | 0.14 | GBX 1,065.94 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Getinge AB | London | Healthcare | Healthcare Equipment & Supplies | £3.91B | 33.9x | -0.94 | GBX 1,428.96 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |